Alternatively, benefit may arise from combination therapy based on agents with non-overlapping mechanisms to reach synergistic or additive mechanism to overcome 5-FU resistance in the MMR deficient subset of colorectal tumors. This evidence concerns the gene MRC1 and colorectal neoplasm.